Results for cetuksimab translation from Croatian to English

cetuksimab + ctx
cetuximab + ctx

erbitux cetuksimab
erbitux cetuximab

cetuksimab (n = 500)
cetuximab (n = 500)

bsc cetuksimab i bsc
bsc cetuximab plus bsc

djelatna tvar je cetuksimab.
the active substance is cetuximab.

terapija zračenjem + cetuksimab
radiation therapy + cetuximab

cetuksimab kao samostalni lijek
cetuximab as a single agent

cetuksimab u kombinaciji s kemoterapijom
cetuximab in combination with chemotherapy

varijabla/statistika cetuksimab i bsc
variable/ statistic cetuximab plus bsc

varijabla/statistika cetuksimab i folfox4
variable/ statistic cetuximab plus folfox4

erbitux sadrži monoklonsko protutijelo cetuksimab.
erbitux contains cetuximab, a monoclonal antibody.

erbitux 5 mg/ml otopina za infuziju cetuksimab
erbitux 5 mg/ml solution for infusion cetuximab

cetuksimab u kombinaciji sa zračenjem za lokalno uznapredovalu bolest
cetuximab in combination with radiation therapy for locally advanced disease

cetuksimab se ne veže na druge receptore koji pripadaju her obitelji.
cetuximab does not bind to other receptors belonging to the her family.

djelatna stvar u lijeku erbitux, cetuksimab, je monoklonalno protutijelo.
the active substance in erbitux, cetuximab, is a monoclonal antibody.

do danas nisu dostupni relevantni podaci o neutralizirajućem učinku haca na cetuksimab.
no conclusive data on the neutralising effect of hacas on cetuximab is available to date.

u svim je ispitivanjuma cetuksimab davan kao što je opisano u poglavlju 4.2.
in all studies, cetuximab was administered as described in section 4.2.

cetuksimab blokira vezanje endogenih egfr liganda što dovodi do inhibicije receptorske funkcije.
cetuximab blocks binding of endogenous egfr ligands resulting in inhibition of the function of the receptor.

cetuksimab u kombinaciji s kemoterapijom na bazi platine kod recidivirajuće i/ili metastatske bolesti
cetuximab in combination with platinum-based chemotherapy in recurrent and/or metastatic disease

ako se dijagnosticira intersticijska bolest pluća, cetuksimab treba ukinuti i bolesnika odgovarajuće liječiti.
if interstitial lung disease is diagnosed, cetuximab must be discontinued and the patient be treated appropriately.